| abstract |
The present invention relates to a method of selecting cells (one or more), tissues (one or more) or cell cultures (one or more) that are sensitive to HSP90 inhibitors. Also described herein are methods for determining the responsiveness of mammalian tumor cells or cancer cells to treatment with an HSP90 inhibitor. Specifically, the present invention provides for an in vitro method for identifying responders or sensitive patients to HSP90 inhibitors and detecting activating mutation (s) of the KRAS gene. The use of oligonucleotides or polynucleotides that can be provided is provided. The invention also relates to a method of monitoring the efficacy of a cancer treatment characterized by the presence of at least one activating mutation of the KARS gene and, optionally, the EGFR gene and / or the BRAF gene. In addition, a method for predicting the efficacy of cancer therapy is described, in particular for cancers characterized by the presence of at least one activating mutation of the KARS gene and, in some cases, the EGFR gene and / or BRAF gene. To do. It also has at least one activating mutation of the KARS gene and, optionally, the EGFR gene and / or the BRAF gene, for screening and / or validation of pharmaceuticals for the treatment of said cancer (trans The use of (genic) non-human animals or (transgenic) cells is described, as well as kits useful for carrying out the methods described herein. |